Abstract
Overview
Introduction
This analysis examines the current position and future outlook for GSK in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
Reasons to Purchase
- Benchmark GSKs performance against key rivals in the ethical pharmaceutical sector
- Learn how GSK will deploy lifecycle management and in-licensing strategies in order to maximize revenues from its mature marketed portfolio
- Understand the challenges of GSKs weak late-stage pipeline, and how these must be met if the promising early pipeline is to have time to deliver
| 
View Cart
